View in EDS HTML Full Text PDF Full Text

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma.

Saved in:
Bibliographic Details
Title: Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma.
Authors: Gavriatopoulou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. mariagabria@gmail.com., Terpos E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Ntanasis-Stathopoulos I; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Malandrakis P; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Eleutherakis-Papaiakovou E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Papatheodorou A; Department of Medical Research, 251 General Air Force Hospital, Athens, Greece., Kanellias N; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Migkou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Fotiou D; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Dialoupi I; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Roussou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Kokkali NA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Kastritis E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Source: Blood cancer journal [Blood Cancer J] 2020 Mar 02; Vol. 10 (3), pp. 25. Date of Electronic Publication: 2020 Mar 02.
Publication Type: Letter
Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32123158
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gavriatopoulou+M%22">Gavriatopoulou M</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. mariagabria@gmail.com.<br /><searchLink fieldCode="AU" term="%22Terpos+E%22">Terpos E</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Ntanasis-Stathopoulos+I%22">Ntanasis-Stathopoulos I</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Malandrakis+P%22">Malandrakis P</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Eleutherakis-Papaiakovou+E%22">Eleutherakis-Papaiakovou E</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Papatheodorou+A%22">Papatheodorou A</searchLink>; Department of Medical Research, 251 General Air Force Hospital, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Kanellias+N%22">Kanellias N</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Migkou+M%22">Migkou M</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Fotiou+D%22">Fotiou D</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Dialoupi+I%22">Dialoupi I</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Roussou+M%22">Roussou M</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Kokkali+NA%22">Kokkali NA</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Kastritis+E%22">Kastritis E</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Dimopoulos+MA%22">Dimopoulos MA</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568469%22">Blood cancer journal</searchLink> [Blood Cancer J] 2020 Mar 02; Vol. 10 (3), pp. 25. <i>Date of Electronic Publication: </i>2020 Mar 02.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Letter
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101568469 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2044-5385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220445385%22">20445385 </searchLink><i>NLM ISO Abbreviation: </i>Blood Cancer J <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32123158
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41408-020-0297-2
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 25
    Titles:
      – TitleFull: Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gavriatopoulou M
      – PersonEntity:
          Name:
            NameFull: Terpos E
      – PersonEntity:
          Name:
            NameFull: Ntanasis-Stathopoulos I
      – PersonEntity:
          Name:
            NameFull: Malandrakis P
      – PersonEntity:
          Name:
            NameFull: Eleutherakis-Papaiakovou E
      – PersonEntity:
          Name:
            NameFull: Papatheodorou A
      – PersonEntity:
          Name:
            NameFull: Kanellias N
      – PersonEntity:
          Name:
            NameFull: Migkou M
      – PersonEntity:
          Name:
            NameFull: Fotiou D
      – PersonEntity:
          Name:
            NameFull: Dialoupi I
      – PersonEntity:
          Name:
            NameFull: Roussou M
      – PersonEntity:
          Name:
            NameFull: Kokkali NA
      – PersonEntity:
          Name:
            NameFull: Kastritis E
      – PersonEntity:
          Name:
            NameFull: Dimopoulos MA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 03
              Text: 2020 Mar 02
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 2044-5385
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Blood cancer journal
              Type: main
ResultId 1